Recent Updates
Recently added Catalysts
WAT Positive Sentiment Score: 75/100

Caspar Tudor, Head of Investor Relations (508) 482-2429 Waters Corporation (NYSE: WAT) Reports Third Quarter 2024 Financial Results Highlights Sales of $740 million exceeded guidance, grew

Key Takeaway: Waters Corporation (NYSE: WAT) reported its financial results for Q3 2024, showcasing strong sales of $740 million, a 4% increase from the previous year. The company's earnings per share also rose, contributing to a positive outlook. Sales growth is expected to be impacted by currency translation, leading to a decrease in projected sales for the full year. However, new product adoption and improved customer spending trends have bolstered confidence in the company's long-term prospects.

Market Sentiment Analysis

Full Press Release Details

Contact: Caspar Tudor, Head of Investor
Relations (508) 482-2429
Waters Corporation (NYSE: WAT) Reports Third Quarter 2024
MILFORD, Mass., November 1, 2024 - Waters Corporation (NYSE: WAT) today announced its financial results for the third quarter of 2024.
Sales for the third quarter of 2024 were $740 million, an increase of 4% as reported, compared to sales of $712 million for the third quarter of 2023.
Currency translation had minimal impact on sales.
On a GAAP basis, diluted earnings per share (EPS) for the third quarter of 2024 was $2.71, compared to
$2.27 for the third quarter of 2023. On a non-GAAP basis, EPS was $2.93, compared to $2.84 for the third quarter of 2023. This includes a headwind of approximately 2% due to unfavorable foreign exchange.
We delivered exceptional third quarter results, fueled by new product adoption and improved customer spending trends, said Dr. Udit Batra,
President & CEO, Waters Corporation. Instruments returned to growth sooner than expected, as liquid chromatography sales to pharma and industrial customers turned positive.
Dr. Batra continued, Looking ahead, our strong commercial execution, competitive product portfolio, and excellent operational performance give us
confidence in the long-term outlook for Waters.
During the third quarter of 2024, sales into the pharmaceutical market increased 2% as reported and 3% in constant currency. Sales into the industrial market
increased 9% as reported and 7% in constant currency. Sales into the academic and government market increased 2% as reported and were flat in constant currency.
During the quarter, instrument system sales increased 1% as reported and in constant currency. Recurring revenues, which represent the combination of service
and precision chemistries, increased 6% as reported and 7% in constant currency.
Geographically, sales in Asia during the quarter increased 5% as
reported and 6% in constant currency. Sales in the Americas increased 1% as reported and in constant currency. Sales in Europe increased 6% as reported and 4% in constant currency.
Unless otherwise noted, sales growth and decline percentages are presented on an as-reported basis. A description and
reconciliation of GAAP to non-GAAP results appear in the tables below and can be found on the Company s website www.waters.com in the Investor Relations section.
Full-Year and Fourth Quarter 2024 Financial Guidance
Full-Year 2024 Financial Guidance
The Company is raising
its full-year 2024 sales guidance, and now expects organic constant currency sales growth to be in the range of -0.9% to -0.3%. Currency translation is expected to
decrease full-year sales growth by 1.2%. M&A contribution from the Wyatt transaction covering the first four-and-a-half
months of the year has added 1.3% to full-year reported sales. The resulting full-year 2024 reported sales growth is expected in the range of -0.8% to -0.2%.
The Company is also raising its full-year 2024 non-GAAP EPS guidance to now be in the range of $11.67 to $11.87, which
includes an estimated headwind of approximately 3% due to unfavorable foreign exchange.
Please refer to the tables below for a reconciliation of the
projected GAAP to non-GAAP financial outlook for the full year.
Fourth Quarter 2024 Financial Guidance
The Company expects fourth quarter 2024 constant currency sales growth to be in the range of +5.0% to +7.0%. Currency translation is expected to
decrease fourth quarter sales growth by 1.7%. The resulting fourth quarter 2024 reported sales growth is expected in the range of +3.3% to +5.3%.
The Company expects fourth quarter 2024 non-GAAP EPS to be in the range of $3.90 to $4.10, which includes an
estimated headwind of approximately 3% due to unfavorable foreign exchange.
Please refer to the tables below for a reconciliation of the projected GAAP
to non-GAAP financial outlook for the fourth quarter.
Conference Call Details
Waters Corporation will webcast its third quarter 2024 financial results conference call today, November 1, 2024, at 8:00 a.m. Eastern Time. To listen to
the call and see the accompanying slide presentation, please visit www.waters.com, select Investor Relations under the About Waters section, navigate to Events & Presentations, and click on the
Webcast. A replay will be available through November 29, 2024, on the same website by webcast and also by phone at (888) 282-0031.
About Waters Corporation
Waters Corporation (NYSE:WAT),
a global leader in analytical instruments and software, has pioneered chromatography, mass spectrometry, and thermal analysis innovations serving the life, materials, food, and environmental sciences for more than 65 years. With approximately 7,500
employees worldwide, Waters operates directly in 35 countries, including 15 manufacturing facilities, and with products available in more than 100 countries. For more information, visit www.waters.com.
Non-GAAP Financial Measures
This press release contains financial measures, such as organic constant currency growth rates, adjusted operating income, adjusted net income, adjusted
earnings per diluted share and free cash flow, among others, which are considered non-GAAP financial measures under applicable U.S. Securities and Exchange Commission rules and regulations. These non-GAAP financial measures should be considered supplemental to, and not a substitute for, financial information prepared in accordance with U.S. generally accepted accounting principles (GAAP). The Company s
definitions of these non-GAAP measures may differ from similarly titled measures used by others. The non-GAAP financial measures used in this press release adjust for
specified items that can be highly variable or difficult to predict. The Company generally uses these non-GAAP financial measures to facilitate management s financial and operational decision-making,
including evaluation of the Company s historical operating results, comparison to competitors operating results and determination of management incentive compensation. These non-GAAP financial
measures reflect an additional way of viewing aspects of the Company s operations that, when viewed with GAAP results and the reconciliations to corresponding GAAP financial measures, may provide a more complete understanding of factors and
trends affecting the Company s business. Because non-GAAP financial measures exclude the effect of items that will increase or decrease the Company s reported results of operations, management
strongly encourages investors to review the Company s consolidated financial statements and publicly filed reports in their entirety. Reconciliations of the non-GAAP financial measures to the most
directly comparable GAAP financial measures are included in the tables accompanying this release.
Cautionary Statement
This release contains forward-looking statements regarding future results and events. For this purpose, any statements that are not statements of
historical fact may be deemed forward-looking statements. Without limiting the foregoing, the words feels , believes , anticipates , plans , expects , intends , suggests ,
appears , estimates , projects and similar expressions, whether in the negative or affirmative, are intended to identify forward-looking statements. The Company s actual future results may differ significantly
from the results discussed in the forward- looking
statements within this release for a variety of reasons, including and without limitation, risks related to, and expectations or ability to realize commercial success of the Wyatt transaction;
the impact of this transaction on the Company s business, anticipated progress on Waters research programs, development of new analytical instruments and associated software or consumables, manufacturing development and capabilities; the
increased indebtedness of the Company as a result of the Wyatt transaction, the repayment of which could impact the Company s future results, market prospects for its products and sales and earnings guidance; foreign currency exchange rate
fluctuations potentially affecting translation of the Company s future non-U.S. operating results, particularly when a foreign currency weakens against the U.S. dollar; current global economic, sovereign
and political conditions and uncertainties, including the effect of new or proposed tariff or trade regulations as well as other new or changed domestic and foreign laws, regulations and policies; changes in inflation and interest rates; the impacts
and costs of war, in particular as a result of the ongoing conflicts between Russia and Ukraine and in the Middle East, and the possibility of further escalation resulting in new geopolitical and regulatory instability; the Chinese government s
ongoing tightening of restrictions on procurement by government-funded customers; the Company s ability to access capital, maintain liquidity and service the Company s debt in volatile market conditions; risks related to the effects of any
pandemic on our business, financial condition, results of operations and prospects; changes in timing and demand for the Company s products among the Company s customers and various market sectors, particularly as a result of fluctuations
in their expenditures or ability to obtain funding; the ability to realize the expected benefits related to the Company s various cost-saving initiatives, including workforce reductions and organizational restructurings; the introduction of
competing products by other companies and loss of market share, as well as pressures on prices from competitors and/or customers; changes in the competitive landscape as a result of changes in ownership, mergers and continued consolidation among the
Company s competitors; regulatory, economic and competitive obstacles to new product introductions; lack of acceptance of new products and inability to grow organically through innovation; rapidly changing technology and product obsolescence;
risks associated with previous or future acquisitions, strategic investments, joint ventures and divestitures, including risks associated with achieving the anticipated financial results and operational synergies; contingent purchase price payments
and expansion of our business into new or developing markets; risks associated with unexpected disruptions in operations; failure to adequately protect the Company s intellectual property, infringement of intellectual property rights of third
parties and inability to obtain licenses on commercially reasonable terms; the Company s ability to acquire adequate sources of supply and its reliance on outside contractors for certain components and modules, as well as disruptions to its
supply chain; risks associated with third-party sales intermediaries and resellers; the impact and costs of changes in statutory or contractual tax rates in jurisdictions in which the Company operates as well as shifts in taxable income among
jurisdictions with different effective tax rates, the outcome of ongoing and future tax examinations and changes in legislation affecting the Company s effective tax rate; the Company s ability to attract and retain qualified employees and
management personnel; risks associated with cybersecurity and technology, including attempts by third parties to defeat the security measures of the Company and its third-party partners; increased regulatory burdens as the Company s business
evolves, especially with respect to the U.S. Food and Drug Administration and U.S. Environmental Protection Agency, among others, and in connection with government contracts; regulatory, environmental and logistical obstacles affecting the
distribution of the Company s products, completion of purchase order documentation and the ability of customers to obtain letters of credit or other financing alternatives; risks associated with litigation and other legal and regulatory
proceedings; and the impact and costs incurred from changes in accounting principles and practices. Such factors and others are discussed more fully in the sections entitled Forward-Looking Statements and Risk Factors of the
Company s annual report
on Form 10-K for the year ended December 31, 2023, as well as in the sections entitled Special Note Regarding Forward-Looking Statements and Risk Factors of the
Company s quarterly reports on Form 10-Q for the quarterly periods ended March 30, 2024 and June 29, 2024, as filed with the Securities and Exchange Commission ( SEC ), which
discussions are incorporated by reference in this release, as updated by the Company s future filings with the SEC. The forward-looking statements included in this release represent the Company s estimates or views as of the date of this
release and should not be relied upon as representing the Company s estimates or views as of any date subsequent to the date of this release. Except as required by law, the Company does not assume any obligation to update any forward-looking
Waters Corporation and Subsidiaries
Consolidated Statements of Operations
(In thousands, except per share data)
Three Months Ended Nine Months Ended
September 28, 2024 September 30, 2023 September 28, 2024 September 30, 2023
Net sales $ 740,305 $ 711,692 $ 2,085,673 $ 2,136,942
Costs and operating expenses:
Cost of sales 301,655 291,407 851,685 876,863
Selling and administrative expenses 169,097 186,748 516,880 555,657
Research and development expenses 45,336 41,995 136,113 130,559
Purchased intangibles amortization 11,759 12,116 35,337 20,410
Litigation provision 1,326 11,568
Operating income 211,132 179,426 534,090 553,453
Other (expense) income, net (338 ) 328 1,619 1,364
Interest expense, net (17,177 ) (26,559 ) (57,824 ) (56,174 )
Income from operations before income taxes 193,617 153,195 477,885 498,643
Provision for income taxes 32,114 18,643 71,449 72,614
Net income $ 161,503 $ 134,552 $ 406,436 $ 426,029
Net income per basic common share $ 2.72 $ 2.28 $ 6.85 $ 7.21
Weighted-average number of basic common shares 59,367 59,093 59,314 59,061
Net income per diluted common share $ 2.71 $ 2.27 $ 6.83 $ 7.19
Weighted-average number of diluted common shares and equivalents 59,504 59,255 59,471 59,262
Waters Corporation and Subsidiaries
Reconciliation of GAAP to Adjusted Non-GAAP
Net Sales by Operating Segments, Products & Services, Geography and Markets
Three Months Ended September 28, 2024 and September 30, 2023
Constant
Three Months Ended Percent Impact of Currency
September 28, 2024 September 30, 2023 Change Currency Growth Rate (a)
NET SALES - OPERATING SEGMENTS
Waters $ 655,652 $ 629,348 4 % 0 % 4 %
TA 84,653 82,344 3 % 1 % 2 %
Total $ 740,305 $ 711,692 4 % 0 % 4 %
NET SALES - PRODUCTS & SERVICES
Instruments $ 323,076 $ 319,431 1 % 0 % 1 %
Service 278,294 263,611 6 % 0 % 6 %
Chemistry 138,935 128,650 8 % 0 % 8 %
Total Recurring 417,229 392,261 6 % (1 %) 7 %
Total $ 740,305 $ 711,692 4 % 0 % 4 %
NET SALES - GEOGRAPHY
Asia $ 251,329 $ 238,228 5 % (1 %) 6 %
Americas 279,136 275,479 1 % 0 % 1 %
Europe 209,840 197,985 6 % 2 % 4 %
Total $ 740,305 $ 711,692 4 % 0 % 4 %
NET SALES - MARKETS
Pharmaceutical $ 430,138 $ 421,535 2 % (1 %) 3 %
Industrial 227,740 209,449 9 % 2 % 7 %
Academic & Government 82,427 80,708 2 % 2 % 0 %
Total $ 740,305 $ 711,692 4 % 0 % 4 %
Waters Corporation and Subsidiaries
Reconciliation of GAAP to Adjusted Non-GAAP
Net Sales by Operating Segments, Products & Services, Geography and Markets
Nine Months Ended September 28, 2024 and September 30, 2023
Organic
Constant
Nine Months Ended Percent Impact of Impact of Currency
September 28, 2024 September 30, 2023 Change Currency Acquisitions Growth Rate (a)
NET SALES - OPERATING SEGMENTS
Waters $ 1,840,112 $ 1,884,658 (2 %) (1 %) 2 % (3 %)
TA 245,561 252,284 (3 %) (1 %) 0 % (2 %)
Total $ 2,085,673 $ 2,136,942 (2 %) (1 %) 2 % (3 %)
NET SALES - PRODUCTS & SERVICES
Instruments $ 859,079 $ 964,380 (11 %) 0 % 3 % (14 %)
Service 812,367 774,478 5 % (1 %) 1 % 5 %
Chemistry 414,227 398,084 4 % (1 %) 0 % 5 %
Total Recurring 1,226,594 1,172,562 5 % (1 %) 1 % 5 %
Total $ 2,085,673 $ 2,136,942 (2 %) (1 %) 2 % (3 %)
NET SALES - GEOGRAPHY
Asia $ 696,319 $ 745,932 (7 %) (3 %) 1 % (5 %)
Americas 794,775 804,827 (1 %) 0 % 3 % (4 %)
Europe 594,579 586,183 1 % 2 % 2 % (3 %)
Total $ 2,085,673 $ 2,136,942 (2 %) (1 %) 2 % (3 %)
NET SALES - MARKETS
Pharmaceutical $ 1,220,092 $ 1,233,177 (1 %) (1 %) 2 % (2 %)
Industrial 644,459 648,754 (1 %) 0 % 1 % (2 %)
Academic & Government 221,122 255,011 (13 %) 1 % 2 % (16 %)
Total $ 2,085,673 $ 2,136,942 (2 %) (1 %) 2 % (3 %)
Waters Corporation and Subsidiaries

Frequently Asked Questions

What were Waters Corporation's Q3 2024 sales figures?

Waters Corporation reported Q3 2024 sales of $740 million, a 4% increase.

How did diluted EPS change in Q3 2024?

Diluted EPS for Q3 2024 was $2.71, up from $2.27 in Q3 2023.

What is the sales growth forecast for Q4 2024?

Q4 2024 sales growth is projected to be between +3.3% and +5.3%.

How did sales in the pharmaceutical sector perform?

Sales into the pharmaceutical market increased by 2% in Q3 2024.

What is the non-GAAP EPS guidance for full-year 2024?

The non-GAAP EPS guidance for 2024 is now $11.67 to $11.87.

Last updated: Nov 1, 2024